People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Corner Therapeutics, Inc. | — | Pharmaceuticals | Series C | $75.3M | $95.3M | 2023 |
Nick Seaver at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nick Seaver on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Altschuler | 1 | 5 |
| Alan Ezekowitz | 1 | 4 |
| Jeffrey Karp | 1 | 3 |
| Jonathan Kagan | 1 | 3 |
| Andrew Bellinger | 1 | 2 |
| Steve Altschuler | 1 | 2 |
| Richard Malley | 1 | 2 |
| Andrew Cornforth | 1 | 1 |
| Garrett Nichols | 1 | 1 |
| Nichols Garrett | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.